Vendors
日本語
search
  2. //
  3. Reports & insights
  4. //
  5. GenAI-oneers In Insurance: EMEA Edition

GenAI-oneers In Insurance: EMEA Edition

Create a vendor selection project
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
We are waiting for the vendor to publish their solution profile. Contact us or request the RFX.
Projects allow you to export Registered Vendor details and survey responses for analysis outside of Marsh CND. Please refer to the Marsh CND User Guide for detailed instructions.
Download Registered Vendor Survey responses as PDF
Contact vendor directly with specific questions (ie. pricing, capacity, etc)
22 July 2024
Nicolas Michellod
Keith Raymond

Abstract

GenAI has rapidly become a technology topic of high importance for insurers. To flesh out the reality, Celent surveyed insurance executives in roles tied to innovation.

In June 2024, we asked them how their sentiments toward GenAI had changed over the prior year, their state of adoption by area, their view of expected impact by use case, and their technology approach, as well as key success factors they identified through their recent experiences.

The headline finding of the Celent survey is that EMEA insurers are in an “early majority” phase of adoption (in production) with a growing proportion moving to production with GenAI within a year.

Our survey also looked at GenAI business cases across the EMEA insurers value chain. The survey results helped us identify where EMEA insurers are prioritizing investment in GenAI. In the survey, Celent spotlighted adoption by area of the insurance value chain.

Client Access